{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:23:02Z","timestamp":1788841382355,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007504","name":"BOSTON MEDICAL CENTER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007504","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.kint.2021.03.028","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T20:40:03Z","timestamp":1618951203000},"page":"289-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy"],"prefix":"10.1016","volume":"100","author":[{"given":"Gabriel B.","family":"Lerner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samarth","family":"Virmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Laurence H.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2021.03.028_bib1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.ajkd.2016.01.030","article-title":"Membranous nephropathy: a journey from bench to bedside","volume":"68","author":"Francis","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.028_bib2","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2215\/CJN.10871016","article-title":"Temporal and demographic trends in glomerular disease epidemiology in the southeastern United States, 1986-2015","volume":"12","author":"O\u2019Shaughnessy","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3181\/00379727-100-24736","article-title":"Production of nephrotic syndrome in rats by Freund\u2019s adjuvants and rat kidney suspensions","volume":"100","author":"Heymann","year":"1959","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.kint.2021.03.028_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.028_bib5","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib6","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1097\/TP.0000000000001056","article-title":"Recurrent membranous nephropathy after kidney transplantation: treatment and long-term implications","volume":"100","author":"Grupper","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2021.03.028_bib7","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ekir.2017.10.013","article-title":"The role of PLA2R antibody in treatment of membranous nephropathy","volume":"3","author":"Dahan","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2021.03.028_bib8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1600-6143.2008.02237.x","article-title":"Recurrent idiopathic membranous nephropathy after kidney transplantation: a surveillance biopsy study","volume":"8","author":"Dabade","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2021.03.028_bib9","volume":"No. 1","year":"2007"},{"key":"10.1016\/j.kint.2021.03.028_bib10","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1053\/j.ajkd.2020.04.013","article-title":"Podocyte antigen staining to identify distinct phenotypes and outcomes in membranous nephropathy: a retrospective multicenter cohort study","volume":"76","author":"Hanset","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2021.03.028_bib12","first-page":"145","article-title":"Pathology of membranous nephropathy","volume":"Vol. 3","author":"Ehrenreich","year":"1968"},{"key":"10.1016\/j.kint.2021.03.028_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1600-6143.2011.03903.x","article-title":"The pathology and clinical features of early recurrent membranous glomerulonephritis","volume":"12","author":"Rodriguez","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.kint.2021.03.028_bib14","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/sj.ki.5000289","article-title":"Renal pathology in idiopathic membranous nephropathy: a new perspective","volume":"69","author":"Troyanov","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-78-1-1","article-title":"Membranous glomerulonephritis: evolution of clinical and pathologic features","volume":"78","author":"Gluck","year":"1973","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2021.03.028_bib16","first-page":"219","article-title":"The development and resolution of glomerular basement membrane changes associated with subepithelial immune deposits","volume":"79","author":"Tornroth","year":"1975","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2021.03.028_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ddmod.2010.11.001","article-title":"Experimental models of membranous nephropathy","volume":"7","author":"Jefferson","year":"2010","journal-title":"Drug Discov Today Dis Models"},{"key":"10.1016\/j.kint.2021.03.028_bib18","first-page":"651","article-title":"Membranous nephropathy: insights from Heymann nephritis","volume":"144","author":"Cavallo","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2021.03.028_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/ki.1973.13","article-title":"Passive transfer of Heymann nephritis with serum","volume":"3","author":"Sugisaki","year":"1973","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib20","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.155.3768.1432","article-title":"Autologous immune-complex pathogenesis of experimental allergic glomerulonephritis","volume":"155","author":"Edgington","year":"1967","journal-title":"Science"},{"key":"10.1016\/j.kint.2021.03.028_bib21","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1172\/JCI109248","article-title":"Experimental glomerulonephritis in the isolated perfused rat kidney","volume":"62","author":"Couser","year":"1978","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.028_bib22","first-page":"502","article-title":"Experimental glomerulonephritis in the rat induced by antibodies directed against tubular antigens. V. Fixed glomerular antigens in the pathogenesis of heterologous immune complex glomerulonephritis","volume":"38","author":"Van Damme","year":"1978","journal-title":"Lab Invest"},{"key":"10.1016\/j.kint.2021.03.028_bib23","doi-asserted-by":"crossref","first-page":"F660","DOI":"10.1152\/ajprenal.00437.2004","article-title":"Experimental membranous nephropathy redux","volume":"289","author":"Cybulsky","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2021.03.028_bib24","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1681\/ASN.V7122518","article-title":"Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis)","volume":"7","author":"Kerjaschki","year":"1996","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.028_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.semnephrol.2013.08.004","article-title":"The role of complement in membranous nephropathy","volume":"33","author":"Ma","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib27","first-page":"1381","article-title":"Differential expression of basement membrane collagen in membranous nephropathy","volume":"139","author":"Kim","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2021.03.028_bib28","first-page":"207","article-title":"Augmented expression of glomerular basement membrane specific type IV collagen isoforms (alpha3-alpha5) in experimental membranous nephropathy","volume":"110","author":"Minto","year":"1998","journal-title":"Proc Assoc Am Physicians"},{"key":"10.1016\/j.kint.2021.03.028_bib29","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1159\/000213505","article-title":"Microarray and bioinformatics analysis of gene expression in experimental membranous nephropathy","volume":"112","author":"Hauser","year":"2009","journal-title":"Nephron Exp Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ki.1993.20","article-title":"Expression of type I collagen mRNA in glomeruli of rats with passive Heymann nephritis","volume":"43","author":"Minto","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib31","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1073\/pnas.79.18.5557","article-title":"The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border","volume":"79","author":"Kerjaschki","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kint.2021.03.028_bib32","first-page":"287","article-title":"Characterization of the antigen (gp600) of Heymann nephritis","volume":"50","author":"Makker","year":"1984","journal-title":"Lab Invest"},{"key":"10.1016\/j.kint.2021.03.028_bib33","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1056\/NEJMoa012895","article-title":"Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies","volume":"346","author":"Debiec","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.028_bib34","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.028_bib35","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1681\/ASN.2018080852","article-title":"Exostosin 1\/exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib37","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib38","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.kint.2020.06.020","article-title":"Moore\u2019s law for membranous nephropathy","volume":"98","author":"Hayashi","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A\u00a0proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib40","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.kint.2020.08.007","article-title":"HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients","volume":"99","author":"Berchtold","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib41","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1681\/ASN.2016010093","article-title":"Long-term exposure to air pollution and increased risk of membranous nephropathy in China","volume":"27","author":"Xu","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib42","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41467-020-15383-w","article-title":"The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis","volume":"11","author":"Xie","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.kint.2021.03.028_bib43","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2014050502","article-title":"Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy","volume":"26","author":"Fresquet","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2013121315","article-title":"Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy","volume":"26","author":"Kao","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib45","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1084\/jem.166.1.109","article-title":"Initial events in the formation of immune deposits in passive Heymann nephritis: gp330-anti-gp330 immune complexes form in epithelial coated pits and rapidly become attached to the glomerular basement membrane","volume":"166","author":"Kerjaschki","year":"1987","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.kint.2021.03.028_bib46","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1172\/JCI85265","article-title":"Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy","volume":"126","author":"Tomas","year":"2016","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.028_bib47","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1172\/JCI119768","article-title":"Pathogenic antibodies inhibit the binding of apolipoproteins to megalin\/gp330 in passive Heymann nephritis","volume":"100","author":"Kerjaschki","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.028_bib48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1074\/jbc.271.1.250","article-title":"Endocytic properties of the M-type 180-kDa receptor for secretory phospholipases A2","volume":"271","author":"Zvaritch","year":"1996","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2021.03.028_bib49","doi-asserted-by":"crossref","first-page":"13583","DOI":"10.1074\/jbc.M108752200","article-title":"Identification of a soluble form phospholipase A2 receptor as a circulating endogenous inhibitor for secretory phospholipase A2","volume":"277","author":"Higashino Ki","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kint.2021.03.028_bib50","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1248\/bpb.27.1165","article-title":"Mammalian phospholipase A(2): phospholipase A(2) receptor","volume":"27","author":"Hanasaki","year":"2004","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.kint.2021.03.028_bib51","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.febslet.2015.02.016","article-title":"C-type lectin-like domain and fibronectin-like type II domain of phospholipase A(2) receptor 1 modulate binding and migratory responses to collagen","volume":"589","author":"Takahashi","year":"2015","journal-title":"FEBS Lett"},{"key":"10.1016\/j.kint.2021.03.028_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029000","article-title":"Soluble THSD7A is an N-glycoprotein that promotes endothelial cell migration and tube formation in angiogenesis","volume":"6","author":"Kuo","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.028_bib53","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/modpathol.2012.237","article-title":"IgG subclass staining in renal biopsies with membranous glomerulonephritis indicates subclass switch during disease progression","volume":"26","author":"Huang","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2021.03.028_bib54","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2215\/CJN.00260112","article-title":"Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy","volume":"7","author":"Del Bello","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib55","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/TP.0b013e3181949e37","article-title":"Donor-directed HLA antibodies before and after transplantectomy detected by the luminex single antigen assay","volume":"87","author":"Billen","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2021.03.028_bib56","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/01.tp.0000196726.91957.97","article-title":"Frequent but late donor-directed antibody formation after kidney transplantectomy within one month after grafting","volume":"81","author":"Lenaers","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.kint.2021.03.028_bib57","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.trre.2018.08.001","article-title":"Indications, risks and impact of failed allograft nephrectomy","volume":"33","author":"Ghyselen","year":"2019","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.kint.2021.03.028_bib58","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.trim.2009.12.005","article-title":"Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant","volume":"22","author":"Marrari","year":"2010","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.kint.2021.03.028_bib59","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab","volume":"93","author":"van de Logt","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib60","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1681\/ASN.2019050538","article-title":"Detection of PLA2R autoantibodies before the diagnosis of membranous nephropathy","volume":"31","author":"Burbelo","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib61","first-page":"89","article-title":"Determinants of glomerular localization of subepithelial immune deposits: effects of altered antigen to antibody ratio, steroids, vasoactive amine antagonists, and aminonucleoside of puromycin on passive Heymann nephritis in rats","volume":"41","author":"Salant","year":"1979","journal-title":"Lab Invest"},{"key":"10.1016\/j.kint.2021.03.028_bib62","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1172\/JCI109987","article-title":"A\u00a0new role for complement in experimental membranous nephropathy in rats","volume":"66","author":"Salant","year":"1980","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2021.03.028_bib63","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/(SICI)1096-9896(199605)179:1<112::AID-PATH542>3.0.CO;2-Q","article-title":"Ultrastructural change of the glomerular basement membrane in rats with Heymann nephritis revealed by ultrahigh resolution scanning electron microscopy","volume":"179","author":"Hironaka","year":"1996","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.kint.2021.03.028_bib64","doi-asserted-by":"crossref","first-page":"790","DOI":"10.2215\/CJN.04120609","article-title":"Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation","volume":"5","author":"Sprangers","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib65","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/ki.2012.209","article-title":"Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy","volume":"82","author":"Hoxha","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib66","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/modpathol.2012.207","article-title":"Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies","volume":"26","author":"Larsen","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2021.03.028_bib67","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ekir.2020.01.018","article-title":"Proteomic analysis of complement proteins in membranous nephropathy","volume":"5","author":"Ravindran","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2021.03.028_bib68","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.kint.2015.12.057","article-title":"Phospholipase A2 receptor staining is absent in many kidney biopsies with early-stage membranous glomerulonephritis","volume":"89","author":"Ryan","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110681","article-title":"PLA2R antibody levels and clinical outcome in patients with membranous nephropathy and non-nephrotic range proteinuria under treatment with inhibitors of the renin-angiotensin system","volume":"9","author":"Hoxha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.028_bib70","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib71","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1681\/ASN.2013040430","article-title":"Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy","volume":"25","author":"Hoxha","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib72","first-page":"491","article-title":"Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus","volume":"34","author":"Segarra-Medrano","year":"2014","journal-title":"Nefrologia"},{"key":"10.1016\/j.kint.2021.03.028_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221293","article-title":"Role of phospholipase A2 receptor 1 antibody level at diagnosis for long-term renal outcome in membranous nephropathy","volume":"14","author":"Mahmud","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.028_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173201","article-title":"Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years","volume":"12","author":"Pourcine","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2021.03.028_bib75","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.2215\/CJN.10471013","article-title":"Association of anti-PLA(2)R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy","volume":"9","author":"Bech","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib76","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMc1011678","article-title":"PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy","volume":"364","author":"Debiec","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.kint.2021.03.028_bib77","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/ndt\/gfs439","article-title":"Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy","volume":"28","author":"Svobodova","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.028_bib78","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1681\/ASN.2015080953","article-title":"Combined assessment of phospholipase A2 receptor autoantibodies and glomerular deposits in membranous nephropathy","volume":"27","author":"Qin","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib79","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib80","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A\u00a010-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib81","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A\u00a0randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib82","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.4049\/jimmunol.142.10.3406","article-title":"Course of transplanted Heymann nephritis kidney in normal host: implications for mechanism of proteinuria in membranous glomerulonephropathy","volume":"142","author":"Makker","year":"1989","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.kint.2021.03.028_bib83","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000045250","article-title":"Preexisting membranous nephropathy in allograft kidney","volume":"81","author":"Nakazawa","year":"1999","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2021.03.028_bib84","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1093\/ndt\/gfu333","article-title":"Membranous nephropathy transplanted in the donor kidney: observations of resolving glomerulopathy in serial allograft biopsies","volume":"29","author":"Mirza","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2021.03.028_bib85","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0090-4295(99)80361-6","article-title":"Successful transplantation of a kidney with early membranous nephropathy","volume":"46","author":"Parker","year":"1995","journal-title":"Urology"},{"issue":"suppl 20","key":"10.1016\/j.kint.2021.03.028_bib86","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1399-0012.2009.00999.x","article-title":"A\u00a0case of living-related renal transplant from the donor with membranous nephropathy","volume":"23","author":"Akioka","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.kint.2021.03.028_bib87","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/1744-9987.12424","article-title":"Donor with membranous nephropathy in preemptive, living-related kidney transplantation","volume":"20","author":"Tsujimura","year":"2016","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kint.2021.03.028_bib88","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.2215\/CJN.01730408","article-title":"Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy","volume":"3","author":"Ruggenenti","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib89","doi-asserted-by":"crossref","first-page":"c145","DOI":"10.1159\/000324762","article-title":"Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated","volume":"119","author":"Barnes","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.kint.2021.03.028_bib90","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2021.03.028_bib91","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2021.03.028_bib92","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fernandez-Juarez","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib93","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.kint.2021.03.028_bib94","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.kint.2018.07.010","article-title":"Deep pockets are not necessarily a good thing in membranous nephropathy: evidence for a modifier allele","volume":"94","author":"Beck","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib95","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.kint.2017.01.012","article-title":"B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab","volume":"92","author":"Rosenzwajg","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2021.03.028_bib96","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.ekir.2020.07.028","article-title":"A\u00a0comprehensive phenotypic and functional immune analysis unravels circulating anti-phospholipase A2 receptor antibody secreting cells in membranous nephropathy patients","volume":"5","author":"Cantarelli","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2021.03.028_bib97","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New \u2018antigens\u2019 in membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382100377X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S008525382100377X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:00:05Z","timestamp":1758762005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525382100377X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S008525382100377X"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2021.03.028","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A conceptual framework linking immunology, pathology, and clinical features in primary membranous nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2021.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}